Riskpilot← Back to searchSign inGet full accessnal von minden AB
ABActiveOrg 5592995657StockholmWholesale of pharmaceutical and medical goods · NACE 4646Est. 20216 employees
Revenue 2024
SEK 6,6M
-1% vs 2023
EBITDA margin
4.8%
-1% vs 2023
Equity ratio
54.3%
Financial strength
Net profit 2024
SEK 244K
-4% vs 2023
| Revenue | SEK 6,6M | -1% |
| EBITDA | SEK 314K | -1% |
| Net profit | SEK 244K | -4% |
| Total assets | SEK 1,7M | +14% |
| Equity | SEK 937K | +35% |
| Employees | 6 | — |
Legal name
nal von minden AB
Org number
5592995657
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 februari 2021
Share capital
SEK 25 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten Firman tecknas var för sig av externa firmatecknarna
Company purpose
Bolaget ska bedriva distribution av medicinska snabbtest samt därmed förenlig verksamhet.
Address
Stockholm
Email
o.laurila@nal-vonminden.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 3 057 | 8 072 | 6 663 | 6 588 |
| Staff expenses | — | — | — | — |
| EBITDA | 179 | 384 | 317 | 314 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | 179 | 384 | 317 | 314 |
| Net financials | −33 | — | 7 | 2 |
| Profit before tax | 146 | 384 | 324 | 315 |
| Tax | −32 | −83 | −71 | −71 |
| Net profit | 114 | 301 | 253 | 244 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 583 | 1 985 | 1 509 | 1 725 |
| Equity | 139 | 440 | 693 | 937 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 444 | 1 545 | 816 | 788 |
| Total debt | 444 | 1 545 | 816 | 788 |
EBITDA margin
4.8%
This company
15.8%
Market median
-70% vs market
20212024
Equity ratio
54.3%
This company
38.2%
Market median
+42% vs market
20212024
Return on equity
26.0%
This company
18.4%
Market median
+41% vs market
20212024
Net profit margin
3.7%
This company
8.1%
Market median
-54% vs market
20212024
Asset turnover
3.82×
This company
1.12×
Market median
+241% vs market
20212024
Debt / equity
0.84×
This company
0.62×
Market median
+35% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
BT | Audit | 2025 |
AO External Signatory | External Signatory | 2021 |
OA External Signatory | External Signatory | 2022 |
| Former (2) | ||
OL External Signatory | External Signatory | 2021 – 2022 |
KK Authorized Recipient of Service | Authorized Recipient of Service | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of nal von minden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Otto Laurila | External Signatory | 0 companies |
| Kerstin Kamp-Wigforss | Authorized Recipient of Service | 0 companies |
| Bengt Tomas Jerker Lundahl | Audit | 0 companies |
| Andreas Ott | External Signatory | 0 companies |
| Otto Antti Valtteri Dunder | External Signatory | 0 companies |
| Roland Johann Meissner | Board of Directors | 0 companies |
| Thomas Zander | Deputy Board Member | 0 companies |
| Lukas Franz Eder | Deputy Board Member | 0 companies |